Drugs / KSP-1007
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05226923 | Jan → Oct 2022 | bacterial infectious disease | Sumitovant Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSP-1007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05226923 ↗ |
| Route | Intravenous | “Single and multiple doses, intravenous administration” NCT05226923 ↗ |